chr17-17222662-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_144997.7(FLCN):c.619-1G>A variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_144997.7 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FLCN | ENST00000285071.9 | c.619-1G>A | splice_acceptor_variant, intron_variant | Intron 6 of 13 | 1 | NM_144997.7 | ENSP00000285071.4 | |||
ENSG00000264187 | ENST00000427497.3 | n.149-3608G>A | intron_variant | Intron 4 of 11 | 1 | ENSP00000394249.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
- -
- -
Birt-Hogg-Dube syndrome Pathogenic:2
Variant summary: FLCN c.619-1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant weakens a 3'- acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 251398 control chromosomes. c.619-1G>A has been reported in the literature in multiple individuals affected with Birt-Hogg-Dube Syndrome (examples- Leter_2008, Houweling_2011). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories cited the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
This sequence change affects an acceptor splice site in intron 6 of the FLCN gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with Birt-Hogg-Dubé syndrome (PMID: 17611575, 27652079). ClinVar contains an entry for this variant (Variation ID: 428657). Studies have shown that disruption of this splice site results in multiple aberrant transcripts, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic. -
FLCN-related disorder Pathogenic:1
The FLCN c.619-1G>A variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in individuals with Birt-Hogg-Dube syndrome (Table 1, Referred to as c.1074-1G>A, Leter et al. 2008. PubMed ID: 17611575; Tables S4 and S7, Hartman et al. 2020. PubMed ID: 32782288; Table 2, Houweling et al. 2011. PubMed ID: 22146830; Table 2, Johannesma et al. 2016. PubMed ID: 27652079). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. It is interpreted as pathogenic in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/428657/). Variants that disrupt the consensus splice acceptor site in FLCN are expected to be pathogenic. This variant is interpreted as pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.619-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 4 of the FLCN gene. This alteration was previously identified in two unrelated families diagnosed with Birt-Hogg-Dube syndrome (Leter EM et al. J. Invest. Dermatol. 2008 Jan;128(1):45-9). Of note, this alteration is also known as c.1074-1G>A in published literature. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at